{"name":"Standard BioTools","slug":"standard-bio","ticker":"LAB","exchange":"NASDAQ","domain":"standardbio.com","description":"Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.","hq":"South San Francisco, CA","founded":0,"employees":"385","ceo":"Michael Egholm","sector":"Life Sciences Tools / Proteomics","stockPrice":0.92,"stockChange":-0.01,"stockChangePercent":-1.08,"marketCap":"$359M","metrics":{"revenue":101937000,"revenueGrowth":-4,"grossMargin":49.9,"rdSpend":25987000,"netIncome":-74896000,"cash":187575008,"dividendYield":0,"peRatio":-30.7,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Standard BioTools reported fourth quarter and full year 2023 financial results, with revenue of $123.4 million and a net loss of $34.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Standard BioTools Announces Collaboration with Biogen to Develop Novel Protein Detection Assays","summary":"Standard BioTools announced a collaboration with Biogen to develop novel protein detection assays for the diagnosis and monitoring of neurological diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQcnZqTDBZTy0xSnZVRXY2YjFDYWdqV2dGZnladGRyWXNtbEVDNXpsMDJONDc2OVZqQkloYm9pT2xfOFhCdFI5TXBUZk9tOFRIMDhwSkllbnJUeDVobjNnUC1fUlY0S1FGTUZGaHVTNkk1U0tHbjZLUzczd3VQY1dZNUxFZUpEZDN3SmJneGc5Nzd5WUw1akhoNUItZ1lOUEJlTFNpMWNzVXNMck1SaFBLNkdFb2k4NTd1d3NjZHJrakVXbXd2?oc=5","date":"2026-03-17","type":"pipeline","source":"MarketBeat","summary":"Standard BioTools Inc. $LAB Shares Purchased by Mak Capital One LLC - MarketBeat","headline":"Standard BioTools Inc. $LAB Shares Purchased by Mak Capital One LLC","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNOERWc0dXQmJfYzN0bGZBVDk5S0hIRF9zZjEtMDZnTDFnYjJ1YkIwbnNKYks3eTR4T19hU040T2ZBZ05fUjJRM2p1RE14eHdHVFpIU00wcV9ZQ3FlSDhsamw1bzFzWUk5OGZ3NkZzUkZwNEJ5R0RqM056dkVNTi1Yd3VWZjF1czFNV2lISEFCbjJXWmd0cTZNRzlmdkhSTXdqOGlJOFE0RWs2MW5SM0cxSVVNOW1HMTVEeXlwLXBnMA?oc=5","date":"2026-03-15","type":"pipeline","source":"MarketBeat","summary":"Standard BioTools Inc. $LAB Stake Boosted by Casdin Capital LLC - MarketBeat","headline":"Standard BioTools Inc. $LAB Stake Boosted by Casdin Capital LLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPdnpRZnFKMXVwaTJRYUpOTHV5WVBuX3o2VHVmZmdWdENocmo0Q1RuMVF0TS1tMG9CWVBNQWpwUmxvcHc4YjZQY3Q1RTRpUDVRdF9BQW0wdUlVSF94S05sMVctTzJtcTB6c0k2VUxhNHZGUXFKb21MMlNIYVV4N3JUeVJvdEx6QWtRamNXYlpoZ1hyVkxQUkVfbC1ydkNrSXprOVVIYVgxckR5WnJMcGdmTjY0bVI?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"STANDARD BIOTOOLS (LAB) director takes 51,282 RSUs in lieu of $60K cash - Stock Titan","headline":"STANDARD BIOTOOLS (LAB) director takes 51,282 RSUs in lieu of $60K cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNNUpxT1hGVVdYNFBhaFd6QkFybGpQcXdWYnlxdkZRQW5ZVDFPWnlTMWZpNTNmcTB0Rnpfci03Y01ZNEpJQnpzYUtGYmQyQTNVeWV4bkprQWFmWjNMWjMtRzJocFczNjVSRjJtWlJkRnZlcUNDVW82WUdSdi02QkUwQUJhNkVBb0xENkx0b3h2UTBzTGVXMzZHQWF4SXhFLXhhLUx2cFVYcw?oc=5","date":"2026-02-24","type":"earnings","source":"investingnews.com","summary":"Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results - investingnews.com","headline":"Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQMnNXVzdKbWhkXzhrRzRmTmQ0bTFWYnAtcXVsZnVyeEx1V2hFNEt5TXlvZU1aSDBhVVpHNGprSGtvcWxaa2Myc3FCbnIxWlpBWmEzOXhEdWVxSFNiMjk4aGJidjFoNmZmNFNBMUZiYWJYUElrbDR3emVfTjhhcVNkRDFQbmR4bXBkVnRBOVRoWHhKRGliNFIwS1U4X3ctRUkzd1NoR1FsTUpGUkFGanRHa1hpS0I?oc=5","date":"2026-02-24","type":"pipeline","source":"Stock Titan","summary":"$550M cash and $1B net operating loss carryforwards: Standard BioTools’ 2026 reset - Stock Titan","headline":"$550M cash and $1B net operating loss carryforwards: Standard BioTools’ 2026 reset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPM0dQV0JqeGlUTWZrN1lQcTQzMTBFWG9GRHpmTlJhWWRWUFYtUUZ6dWVQa1F2cXhRM3AwZ0RMWkRpOWhPVk1JRkd6Ty1CaTRGU0loZWpfaHc2d05ZMHI3V1lNb0tvSVNOd0ZXeTRSVEFqRlpGVjRDUWJyQmxHSzVxZmF1cm9McnZqbEtDZHlibGZWUGYwLTlDT2hnNHhlcERaeGpwYjQ4ZUhwUk9WNHJqZm0wRkw5QQ?oc=5","date":"2026-02-24","type":"earnings","source":"TipRanks","summary":"Standard BioTools Details SomaLogic Sale and Profitability Path - TipRanks","headline":"Standard BioTools Details SomaLogic Sale and Profitability Path","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-12","type":"pipeline","source":"simplywall.st","summary":"Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st","headline":"Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27%","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-10","type":"earnings","source":"The Manila Times","summary":"Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - The Manila Times","headline":"Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026","sentiment":"neutral"},{"date":"2026-01-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-31","type":"pipeline","source":"simplywall.st","summary":"Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80% - simplywall.st","headline":"Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQY0FVTDdib0lMV2tqY3lsbUgyeGVJajFnTjZMaEZFQkFyeWNSSnRmN2x1NTB6MFVMdGNZd0JWcWdQQUZxQUxDVGEtWGJxd2RYR2VDcjI5QkJ5Z0pDUVYtcENieGRzYkg1dUxreGk4czU5ZXNkZmhTckplRk9lazg1b0UyNkQ?oc=5","date":"2025-12-28","type":"pipeline","source":"Seeking Alpha","summary":"Standard BioTools: Outlook Still Murky (NASDAQ:LAB) - Seeking Alpha","headline":"Standard BioTools: Outlook Still Murky (NASDAQ:LAB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNYlQ2cUJqd2l5aWR1UFAtS3p1TEpXNGNYQkViOWNYQ2JsSzZaZDVrbHM3SEdONXFIdTRJZE9LbzItZWRnQVNEMnhTR3J6VDQ1REVJWjdkcUxZOVQxb1BLX2lfWlRkMVFCMG1CR1BQcno4NGQ0SE5zUVlaMVA5c0JKa0pOcG9Cd185U05KT2pnWmVHNTRpMTE3VlVJLVUtMzlYN2tvMmo1MDFFSXBjUTltNVNYZDY3bzNTRU55emNFT2ZqSnFVWngzODM3TmlkZlZJRWEzUGp5MUdNYjR4aXZEZER4eVNJam5KMVhqeTAyaURZM1hFZGp1c3ZIeEVfVVU?oc=5","date":"2025-06-23","type":"trial","source":"GlobeNewswire","summary":"Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina - GlobeNewswire","headline":"Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bio-Rad Laboratories","Thermo Fisher Scientific","Agilent Technologies"],"therapeuticFocus":["Proteomics","Life Sciences Tools"],"financials":{"source":"sec_edgar","revenue":101937000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":101937000,"period":"2017-12-31"},{"value":27745000,"period":"2017-12-31"},{"value":24747000,"period":"2017-09-30"},{"value":23912000,"period":"2017-06-30"},{"value":25533000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":25987000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74896000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":567754000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.92,"previousClose":0.93,"fiftyTwoWeekHigh":1.72,"fiftyTwoWeekLow":0.88,"fiftyTwoWeekRange":"0.88 - 1.72","fiftyDayAverage":1.11,"twoHundredDayAverage":1.28,"beta":1.42,"enterpriseValue":204068144,"forwardPE":-30.7,"priceToBook":0.75,"priceToSales":4.21,"enterpriseToRevenue":2.39,"enterpriseToEbitda":-2.48,"pegRatio":0,"ebitda":-82328000,"ebitdaMargin":-96.5,"freeCashflow":-171834880,"operatingCashflow":-74343000,"totalDebt":30827000,"debtToEquity":7.3,"currentRatio":4.19,"returnOnAssets":-9.9,"returnOnEquity":-13.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":2,"targetMeanPrice":1.55,"targetHighPrice":1.75,"targetLowPrice":1.35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.5,"institutionHeldPercent":77.4,"sharesOutstanding":390071506,"floatShares":216899261,"sharesShort":8281198,"shortRatio":3.24,"shortPercentOfFloat":2.1,"epsTrailing":-0.15,"epsForward":-0.03,"revenuePerShare":0.22,"bookValue":1.23,"officers":[{"age":62,"name":"Dr. Michael  Egholm Ph.D.","title":"President, CEO & Director"},{"age":54,"name":"Mr. Hanjoon  Kim","title":"Chief Financial Officer"},{"age":43,"name":"Mr. Sean  Mackay","title":"Chief Business Officer & Senior VP"},{"age":null,"name":"Mr. Jonathan  Mickelsen","title":"VP & Chief Accounting Officer"},{"age":null,"name":"John  Graziano","title":"Vice President of Investor Relations"},{"age":51,"name":"Ms. Elizabeth R. Jensen","title":"Chief Human Resources Officer"},{"age":null,"name":"Mr. Mike  Musgnug","title":"Senior VP & Chief Commercial Officer"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.standardbio.com","phone":"650 266 6000"}}